Page 791 - Cardiac Nursing

6
6
/
0
/
/
0
/
009
1
1
009
2
2
009
68.
68.
qx
68.
5
3-7
3-7
qx
0
0
0
3
d
d
3
Pa
g
g
Pa
M
M
M
e 7
Apt
ara
ara
Apt
e 7
67
67
4 A
A
A
4 A
2:0
2:0
2:0
A
A
A
A
A
A
A
A
LWB
LWB
K34
p7
p7
LWBK340-c32_p7553-768.qxd 30/06/2009 12:04 AM Page 767 Aptara
0-c
32_
32_
0-c
K34
K34
CHAP TER 3 2 / Coronary Heart Disease Risk Factors 767
117. Lindquist, O., Bengtsson, C., & Lapidus, L. (1985). Relationships be- hormone replacement therapy in postmenopausal women. BMJ,
5
tween the menopause and risk factors for ischaemic heart disease. Acta 335(7613), 239.
5
0
Obstetrica Gynecologica Scandia Supplement, 130, 43–47. 140. ACOG. (2002). http: and www.acog.org/from_home/publications/
0
118. Matthews, K. A., Meilhan, E., Kuller, L. H., et al. (1989). Menopause a press_releases/nr08-30-02.cfm. Alpha Tocopherol, Beta Carotene Cancer
risk factor for coronary heart disease. New England Journal of Medicine, Prevention Study Group (1994). The effect of vitamin E and beta
321, 641–646. carotene on the incidence of lung cancer and other cancers in male smok-
119. Mann, J. I., Vessey, M. P., Thorogood, M., et al. (1975). Myocardial in- ers. New England Journal of Medicine, 330, 1029–1035.
farction in young women with special reference to oral contraceptive 141. Bates, C. J., Mansoor, M. A., van der Pols, J., et al. (1997). Plasma total
2
practice. BMJ, 2, 241–245. homocysteine in a representative sample of 972 British men and women
2
120. Mann, J. I., & Inman, W. H. W. (1975). Oral contraceptives and death aged 65 and over. European Journal of Clinical Nutrition, 51, 691–697.
from myocardial infarction. BMJ, 2, 245–248. 142. Dalery, K., Lussier-Cacan, S., Selhub, J., et al. (1995). Homocysteine
2
2
121. Jick, H., Dinan, B., & Rothman, K. J. (1978). Oral contraceptives and and coronary artery disease in French Canadian subjects: Relation with
9
nonfatal myocardial infarction. JAMA, 239, 1403–1406. vitamins B 12 , B 6 , pyridoxal phosphate, and folate. American Journal of
9
122. Kelleher, C. C. (1990). Clinical aspects of the relationship between oral Cardiology, 75, 1107–1111.
5
5
contraceptives and abnormalities of the hemostatic system: Relation to 143. Malinow, M. R., Bostom, A. G., & Krauss, R. M. (1999). Homocyst(e)
the development of cardiovascular disease. American Journal of Obstetrics ine, diet, and cardiovascular diseases: A statement for healthcare profes-
and Gynecology, 163, 392–395. sionals from the Nutrition Committee, American Heart Association.
9
123. Meade, T. W. (1988). Risks and mechanisms of cardiovascular events in Circulation, 99, 178–182.
9
users of oral contraceptives. American Journal of Obstetrics and Gynecol- 144. Selhub, J., Jacques, P. F., Wilson, P. W. F., et al. (1993). Vitamin status
8
8
ogy, 158, 1646–1652. and intake as primary determinants of homocysteinemia in an elderly
0
0
124. Rosenberg, L., Palmer, J. R., Lesko, S. M., et al. (1990). Oral contracep- population. JAMA, 270, 2693–2698.
tive use and the risk of myocardial infarction. American Journal of Epi- 145. Schwartz, S. M., Siscovick, D. S., Malinow, M. R., et al. (1997). Myocar-
demiology, 131, 1009–1016. dial infarction in young women in relation to plasma total homocysteine,
125. Mant, J., Painter, R., & Vessey, M. (1998). Risk of myocardial infarction, folate, and a common variant in the methylenetetrahydrofolate reductase
6
6
angina and stroke in users of oral contraceptives: An updated analysis of gene. Circulation, 96, 412–417.
5
a cohort study. British Journal of Obstetrics and Gynaecology, 105, 146. Mangoni, A. A., & Jackson, S. H. (2002). Homocysteine and cardiovas-
890–896. cular disease: Current evidence and future prospects. American Journal of
2
2
126. Sidney, S., Siscovick, D. S., Petitti, D. B., et al. (1998). Myocardial in- Medicine, 112, 556–565.
farction and use of low-dose oral contraceptives: A pooled analysis of 2 147. Kang, S., Wong, P. W. K., Cook, H. Y., et al. (1986). Protein-bound ho-
US studies. Circulation, 98, 1058–1063. mocysteine, a possible risk factor for coronary artery disease. Journal of
8
127. Stampfer, M. J., Willett, W. C., Colditz, G. C., et al. (1988). A prospec- Clinical Investigation, 77, 1482–1486.
7
7
tive study of past use of oral contraceptive agents and risk of cardiovas- 148. Robinson, K., Mayer, E. L., Miller, D. P., et al. (1995). Hyperhomocys-
R
R
cular diseases. New England Journal of Medicine, 319, 1313–1317. teinemia and low pyridoxal phosphate, common and independent reversible
9
9
128. Stampfer, M. J., Willett, W. C., Colditz, G. C., et al. (1990). Past use of risk factors for coronary artery disease. Circulation, 92, 2825–2830.
2
2
oral contraceptives and cardiovascular disease: A meta-analysis in the 149. Selhub, J., Jacques, P. F., Bostom, A. G., et al. (1995). Association between
context of the Nurses’ Health Study. American Journal of Obstetrics and plasma homocysteine concentrations and extracranial carotid-artery
2
Gynecology, 163, 285–291. stenosis. New England Journal of Medicine, 332, 286–291.
2
129. Goldbaum, G. M., Kendrick, J. S., Hogelin, G. C., et al. (1987). The rel- 150. Malinow, M. R., Nieto, F. J., Szklo, M., et al. (1993). Carotid artery in-
ative impact of smoking and oral contraceptive use on women in the timal-medial wall thickening and plasma homocysteine in asymptomatic
8
United States. JAMA, 258, 1339–1342. adults. Circulation, 87, 1107–1113.
7
7
130. Graff-Iversen, S., Hammar, N., Thelle, D. S., et al. (2006). Use of oral 151. Van Der Mooren, M. J., Wouters, M. G., Blom, H. J., et al. (1994). Hor-
contraceptives and mortality during 14 years’ follow-up of Norwegian mone replacement therapy may reduce high serum homocysteine in
4
4
women. Scandinavian Journal of Public Health, 34(1), 11–16. postmenopausal women. European Journal of Clinical Investigation, 24,
4
4
131. Newton, K. M., LaCroix, A. Z., McKnight, B., et al. (1997). Estrogen 733–736.
replacement therapy and prognosis after first myocardial infarction. 152. Brattstrom, L. E., Hultberg, B. L., & Hardebo, J. E. (1985). Folic acid
5
American Journal of Epidemiology, 145, 269–277. responsive postmenopausal homocysteinemia. Metabolism, 34,
5
4
4
132. Grodstein, F., & Stampfer, M. (1995). The epidemiology of coronary 1073–1077.
heart disease and estrogen replacement in postmenopausal women. 153. Toole, J. F., Malinow, M. R., Chambless, L. E., et al. (2004). Lowering
Progress in Cardiovascular Disease, 38, 199–210. homocysteine in patients with ischemic stroke to prevent recurrent stroke,
8
8
133. Hulley, S., Grady, D., Bush, T., et al. (1998). Randomized trial of estro- myocardial infarction, and death: The Vitamin Intervention for Stroke
gen plus progestin for secondary prevention of coronary heart disease in Prevention (VISP) randomized controlled trial. JAMA, 291(5), 565–575.
postmenopausal women. Heart and Estrogen/progestin Replacement 154. Bonaa, K. H., Njolstad, I., Ueland, P. M., et al. (2006). Homocysteine
Study (HERS) Research Group. JAMA, 280, 605–613. lowering and cardiovascular events after acute myocardial infarction.
0
0
134. Design of the Women’s Health Initiative clinical trial and observational New England Journal of Medicine, 354(15), 1578–1588.
4
4
study. The Women’s Health Initiative Study Group. (1998). Control 155. The Heart Outcomes Prevention Evaluation. (2006). Homocysteine
Clinical Trials, 19(1), 61–109. lowering with folic acid and B vitamins in vascular disease. New England
135. Writing Group for the Women’s Health Initiative Investigators. (2002). Journal of Medicine, 354(15), 1567–1577.
4
4
Risks and benefits of estrogen plus progestin in healthy postmenopausal 156. Schwammenthal, Y., & Tanne, D. (2004). Homocysteine, B-vitamin
women: Principal results from the Women’s Health Initiative randomized supplementation, and stroke prevention: From observational to inter-
8
controlled trial. JAMA, 288, 321–333. ventional trials. The Lancet Neurology, 3(8), 493–495.
W
W
136. Women’s Health Initiative Steering, C. (2004). Effects of conjugated 157. Lonn, E. (2007). Homocysteine in the prevention of ischemic heart dis-
equine estrogen in postmenopausal women with hysterectomy: The ease, stroke and venous thromboembolism: Therapeutic target or just an-
Women’s Health Initiative Randomized Controlled Trial. JAMA, other distraction? Current Opinion in Hematology, 14(5), 481–487.
4
4
291(14), 1701–1712. 158. Marcus, J., Sarnak, M. J., & Menon, V. (2007). Homocysteine lowering
137. Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., et al. (2000). and cardiovascular disease risk: Lost in translation. Canadian Journal of
Effects of estrogen replacement on the progression of coronary-artery Cardiology, 23(9), 707–710.
atherosclerosis. New England Journal of Medicine, 343, 522–529. 159. Wierzbicki, A. S. (2007). Homocysteine and cardiovascular disease: A re-
4
4
138. Angerer, P., Strok, S., Kothny, W., et al. (2001). Effect of oral post- view of the evidence. Diabetes and Vascular Disease Research, 4(2), 143–150.
menopausal hormsone replacement on progression of atherosclerosis: A 160. Diaz, M. N., Frei, B., Vita J. A., et al. (1997). Mechanisms of disease, an-
randomized, controlled trial. Arteriosclerosis Thrombosis Vascular Biology, tioxidants and atherosclerotic heart disease. New England Journal of Med-
7
7
21, 262–268. icine, 337, 408–416.
139. Vickers, M. R., MacLennan, A. H., Lawton, B., et al. (2007). Main mor- 161. Steinbrecher, U. P. (1997). Dietary antioxidants and cardioprotection:
V
V
5
bidities recorded in the women’s international study of long duration oe- Fact or fallacy? Canadian Journal of Physiology and Pharmacology, 75,
5
strogen after menopause (WISDOM): A randomised controlled trial of 228–233.